Navigation Links
Targeted drug therapy prevents exercise-induced arrhythmias
Date:3/29/2009

flecainide is going to allow us to back off the excessively high doses of beta blockers, limit defibrillator discharges in patients with ICDs, and decrease the likelihood that we'll need to implant defibrillators in these patients at a young age if the arrhythmias can be controlled medically," Fish said. "That's an exciting prospect."

Fish feels like he's come full circle with flecainide. In the late 1980s, he surveyed the drug's effects in pediatric patients as a follow-up to a large clinical trial in adults that showed increased rates of death among heart attack survivors who had ventricular arrhythmias. Fish and his colleagues found an unexpectedly high frequency of pro-arrhythmia among young patients.

"So for 20 years, physicians have been reluctant to use flecainide for ventricular arrhythmias," Fish said. "It's interesting to now find ourselves turning to a medication we've been fearful of using. In this specific population (CPVT patients), it may turn out to be the magic bullet."


'/>"/>

Contact: Craig Boerner
craig.boerner@vanderbilt.edu
615-322-4747
Vanderbilt University Medical Center
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. St. Jude finds factors that accelerate resistance to targeted therapy in lymphoblastic leukemia
2. Microarray sequence capture speeds large-scale resequencing of targeted genomic regions
3. Researchers combat slowing yields with targeted fertilizer applications
4. Fishing throws targeted species off balance, Scripps study shows
5. New technique allows targeted inactivation of genes in research model
6. Newly identified role for power plants in human cells could lead to targeted therapies
7. Consortium develops new method enabling routine targeted gene modification
8. On the trail of a targeted therapy for blood cancers
9. Cellular discovery may lead to targeted treatment for rare form of anemia
10. Molecular fingerprints point the way to earlier cancer diagnosis and more targeted treatment
11. A new radiation therapy treatment developed for head and neck cancer patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... , Dec. 16, 2014 Valencell, a leader ... PerformTek biometric technology to industry leaders such as Intel, ... clinically validated, biometric wearable products. These products will be ... Las Vegas . ... accurate, flexible and robust – with the clinical data ...
(Date:12/11/2014)... Research and Markets , ... http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the addition of the ... to their offering. One major ... of multimodal biometric systems. Multimodal biometric systems utilize ... verification and identification purposes. This helps to reduce ...
(Date:12/10/2014)... , Dec. 9, 2014  Wake Forest Baptist Medical ... building for its School of Medicine. Funding for this ... capital campaign that will be publicly launched next summer. ... located in the former 60 series R.J. Reynolds Tobacco ... Quarter. Construction will begin immediately with plans to be ...
Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
... be expensive, time-consuming for clinicians, and tedious for children, who ... number of blood draws. A new calculation eliminates many of ... be performed in a clinical setting to offer an accurate ... formula, developed from a study that will appear in the ...
... Solution Matches More Than 10 Million ... Neurotechnology, a provider of high-precision ... MegaMatcher Accelerator, a packaged hardware and ... (1:N) biometric fingerprint and face matching ...
... summit on engineering solutions to major challenges facing ... from Duke University. Topics to be addressed include ... and education and learning. The streaming event ... The summit is in response to the Grand ...
Cached Biology News:Updated formula measures kidney function more accurately 2Updated formula measures kidney function more accurately 3New MegaMatcher Accelerator Boosts Speed for High-Volume Biometric Identification and Database Duplicate Searching 2New MegaMatcher Accelerator Boosts Speed for High-Volume Biometric Identification and Database Duplicate Searching 3Live webcasting of global engineering summit 2
(Date:12/15/2014)... 15, 2014  Ascendis Pharma A/S, a biotechnology ... address significant unmet medical needs, today announced positive ... pediatric study to evaluate once-weekly TransCon Growth Hormone ... This interim analysis consists of 25 patients, representing ... the study, completing all six months of treatment. ...
(Date:12/13/2014)... and Virgin Unite Canada, the non-profit foundation of the Virgin ... Canadian entrepreneurs tackling social and environmental challenges. Today, Sir ... Centre to announce the new partnership, which includes the development ... $1 million in seed capital provided by Virgin Unite Canada ... Foundation, founded by Alison Lawton . ...
(Date:12/13/2014)... 12, 2014 The DNA Microarray ... 2013, and is expected to grow at a ... Browse through the TOC of the DNA Microarray ... and segments, with help of various tables and ... DNA Microarray market consists of instrument, consumables, and ...
(Date:12/13/2014)... The “Global Synthetic Biology Market (2013-2018)”, analyses and ... challenges. , The global synthetic biology market is ... Scientific, Inc. (U.S.), DuPont (U.S.), and Royal DSM ... ~65% of the total synthetic biology market. ... @ http://www.marketsandmarkets.com/Market-Reports/synthetic-biology-market-889.html , Thermo Fisher Scientific, ...
Breaking Biology Technology:Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4MaRS and Virgin Unite partner to invest in business as a force for good 2MaRS and Virgin Unite partner to invest in business as a force for good 3DNA Microarray Market Is Expected to Grow at a CAGR of 15.2% from 2014 to 2019 - A Report by MicroMarket Monitor 2DNA Microarray Market Is Expected to Grow at a CAGR of 15.2% from 2014 to 2019 - A Report by MicroMarket Monitor 3DNA Microarray Market Is Expected to Grow at a CAGR of 15.2% from 2014 to 2019 - A Report by MicroMarket Monitor 4Synthetic Biology Market to HIt $5.6304 Billion by 2018 - New Research Report by MarketsandMakets 2Synthetic Biology Market to HIt $5.6304 Billion by 2018 - New Research Report by MarketsandMakets 3
... PODD ), the manufacturer and marketer of ... DeSisto, Chief Executive,Officer, will participate in the Thomas ... present an overview of the Company,at 3:50 p.m. ... Four Seasons Hotel in,Boston, MA. During the ...
... DCGN ) today announced that it will host ... the Thomas Weisel Partners Annual,Healthcare Conference. The presentation ... at the Four Seasons, Boston. The webcast can be ... and those,interested in listening should log on a ...
... CAMBRIDGE, Mass., Aug. 29 Millennium,Pharmaceuticals, Inc. ... its presentation,at the Thomas Weisel Partners 2007 ... be accessed by visiting the Investors section ... (Logo: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO ) The ...
Cached Biology Technology:Thomas Weisel Partners 2007 Healthcare Conference To Webcast Millennium Presentation 2
Chicken polyclonal to QPRT ( Abpromise for all tested applications). Antigen: Synthetic peptide, corresponding to Internal sequence amino acids 123-237 of Human QPRT Entrez Gene ID: 23475 ...
Antibody Diluent for IHC 125 ml...
QPRT Antibody...
Mouse monoclonal [4C4] to Y14 ( Abpromise for all tested applications). entrezGeneID: 9939 SwissProtID: Q9Y5S9...
Biology Products: